SCHEMBL109929

SCHEMBL109929

Cc1cc(Br)cc(Br)c1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.43
TSHR P16473 4/20 0.43
TDP1 Q9NUW8 3/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.38
POLB P06746 1/20 0.37
CYP2D6 P10635 2/20 0.36
SLC6A4 P31645 2/20 0.36
KCNH2 Q12809 2/20 0.36
ABCB11 O95342 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
AR P10275 1/20 0.36
SLC6A2 P23975 1/20 0.36
PDE4A P27815 1/20 0.36
SLC6A3 Q01959 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
HTT P42858 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL28652019 0.97 CYP3A4 (0.42) CYP3A4TSHRTDP1ALDH1A1MAPT
SCHEMBL146892 0.86 ALDH1A1 (0.58) CYP3A4TSHRTDP1ALDH1A1MAPT
SCHEMBL29210 0.80 GAA (0.65) CYP3A4TSHRTDP1ALDH1A1MAPT
SCHEMBL1392743 0.79 ALDH1A1 (0.65) CYP3A4TSHRTDP1ALDH1A1MAPT
SCHEMBL159075 0.79 ALDH1A1 (0.43) CYP3A4TSHRTDP1ALDH1A1MAPT
SCHEMBL80048 0.79 KDM4E (0.45) CYP3A4TSHRTDP1ALDH1A1MAPT
SCHEMBL8132358 0.79 MAPT (0.65) CYP3A4TSHRTDP1ALDH1A1MAPT
Bromide SCHEMBL10915130 0.77 KDM4E (0.43) CYP3A4TSHRTDP1ALDH1A1MAPT
SCHEMBL2427550 0.75 CYP3A4 (0.40) CYP3A4TSHRTDP1ALDH1A1MAPT
SCHEMBL5346206 0.75 CYP3A4 (0.40) CYP3A4TSHRTDP1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118619842-A Preparation method of 2-amino-5-bromo-N, 3-dimethylbenzamide 浙江予睿化学科技有限公司 2024-09-10 CN claimed
EP-0150787-A2 Compound having antibronchopneumopathic activity, process for its preparation and pharmaceutical compositions containing it PULITZER ITALIANA S.p.A. (IT) 1985-08-07 EP claimed
EP-3927685-B1 A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF PI INDUSTRIES LTD (IN) 2025-10-08 EP disclosed
CN-111065626-B Compounds for the treatment of huntington's disease PTC医疗公司 2024-09-27 CN disclosed
CN-118619842-A Preparation method of 2-amino-5-bromo-N, 3-dimethylbenzamide 浙江予睿化学科技有限公司 2024-09-10 CN disclosed
CN-118619842-A Preparation method of 2-amino-5-bromo-N, 3-dimethylbenzamide 浙江予睿化学科技有限公司 2024-09-10 CN disclosed
US-11718584-B2 Process for the synthesis anthranilic diamide compounds and intermediates thereof PI INDUSTRIES LTD. (IN) 2023-08-08 US disclosed
US-11718584-B2 Process for the synthesis anthranilic diamide compounds and intermediates thereof PI INDUSTRIES LTD. (IN) 2023-08-08 US disclosed
US-11718584-B2 Process for the synthesis anthranilic diamide compounds and intermediates thereof PI INDUSTRIES LTD. (IN) 2023-08-08 US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 US disclosed
WO-2012007352-A1 AQUEOUS COMPOSITION COMPRISING BROMHEXINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-19 WO disclosed
EP-1988144-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENCE ELEMENT, DISPLAY DEVICE AND ILLUMINATING DEVICE KONICA MINOLTA HOLDINGS, INC. (JP) 2008-11-05 EP disclosed
US-20080242685-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-10-02 US disclosed
WO-2007023072-A2 USE OF AMBROXOL FOR THE TREATMENT OF RHINOVIRUS INFECTIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-03-01 WO disclosed
US-4925984-A REACTION WITH BROMINE IN SOLUTION ETHYL CORPORATION (US) 1990-05-15 US disclosed
EP-0150787-A2 Compound having antibronchopneumopathic activity, process for its preparation and pharmaceutical compositions containing it PULITZER ITALIANA S.p.A. (IT) 1985-08-07 EP disclosed
US-4233055-A Quaternary ammonioalkanecarboxylic acid anilides as plant growth influencing agents CIBA-GEIGY CORPORATION (US) 1980-11-11 US disclosed
US-4141718-A ANTIGROWTH AGENTS FOR PLANTS CIBA-GEIGY CORPORATION (US) 1979-02-27 US disclosed
US-3978040-A Process for the preparation of cyanoazo compounds by reacting halogenoazo compounds with CuCN in an aqueous media in the presence of a nitrogen base BAYER AKTIENGESELLSCHAFT (DT) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718584-B2 Process for the synthesis anthranilic diamide compounds and intermediates thereof DAO, DDC, QDPR CYP3A4 44/4885TSHR 1587/4885TDP1 4302/4885
US-20080242685-A1 Chemical Compounds NFKBIA, IKBKG, NFKB2 CYP3A4 1275/4885TSHR 2303/4885TDP1 1044/4885
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP CYP3A4 1364/4885TSHR 3407/4885TDP1 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.